Evaluation of the Effects of Corticosteroids on Histamine Release by ex Vivo Cutaneous Microdialysis 233
ing the potency of corticosteroids according to MacKen-
zie classification and the inhibition of histamine release.
These results show us that a new classification of the po-
tency of corticosteroids should be established to treat
correctly the patients according to the origin of the ob-
served disturbances. These results invite us to consider
the power of topical corticosteroids differently depending
on their target action (anti-allergic, anti-inflammatory...).
New ex vivo models should be developed in order to ob-
serve the direct effects of corticosteroids on the release of
inflammatory mediators. The method, which we have de-
veloped, should lead to the study of clinical disease mo-
dels for immuno-allergic clinical validation.
REFERENCES
[1] A. W. MacKenzie and R. B. Stoughton, “A Method for
Comparing Percutaneous Absorption of Steroids,” Archi-
ves of Dermatology, Vol. 86, No. 11, 1962, pp. 608-610.
doi:10.1001/archderm.1962.01590110044005
[2] A. W. McKenzie, “Percutaneous Absorption of Steroids,”
Archives of Dermatology, Vol. 86, No. 11, 1962, pp. 611-
614. doi:10.1001/archderm.1962.01590110047006
[3] S. Wiedersberg, C. S. Leopold and R. H. Guy, “Bioavai-
lability and Bioequivalence of Topical Glucocorticoids,”
European Journal of Pharmaceutics and Biopharmaceu-
tics, Vol. 68, No. 3, 2008, pp. 453-466.
doi:10.1016/j.ejpb.2007.08.007
[4] Y. Narkar, “Bioequivalence for Topical Products—An
Update,” Pharmaceutical Research, Vol. 27, No. 12,
2010, pp. 2590-2601. doi:10.1007/s11095-010-0250-3
[5] Organisation for Economic Co-operation and Develop-
ment (OECD), “Test Guideline 427: In Vitro Method,”
Paris, 2004.
[6] T. J. Franz, P. A. Lehman and S. G. Raney, “Use of Ex-
cised Human Skin to Assess the Bioequivalence of To-
pical Products,” Skin Pharmacology and Physiology, Vol.
22, No. 5, 2009, pp. 276-286. doi:10.1159/000235828
[7] A. Le Quellec, S. Dupin, P. Genissel, S. Saivin, B. Marc-
hand and J. P. M. Houin, “Microdialysis Probes Calibra-
tion: Gradient and Tissue Dependent Changes in No Flux
and Reverse Dialysis Methods,” Journal of Pharmaco-
ogical and Toxicological Methods, Vol. 33, No. 1, 1995,
pp. 11-16. doi:10.1016/1056-8719(94)00049-A
[8] N. Leveque, S. Makki, J. Hadgraft and P. Humbert,
“Comparison of Franz Cells and Microdialysis for As-
sessing Salicylic Penetration through Human Skin,” Inter-
national Journal of Pharmaceutics, Vol. 269, No. 2, 2004,
pp. 323-328. doi:10.1016/j.ijpharm.2003.09.012
[9] I. Brody, “Mast Cell Degranulation in the Evolution of
Acute Eruptive Guttate Psoriasis Vulgaris,” Journal of In-
vestigative Dermatology, Vol. 82, No. 5, 1984, pp. 460-
464. doi:10.1111/1523-1747.ep12260955
[10] A. L. Krogstad, G. Lonnroth, B. F. G. Larson and B. G.
Wallin, “Nerve-Induced Histamine Release Is of Little
Importance in Psoriatic Skin,” British Journal of Dermat-
ology, Vol. 139, No. 5, 1998, pp. 403-409.
doi:10.1046/j.1365-2133.1998.02402.x
[11] T. Ishizaka, D. H. Conrad, T. F. Huff, D. D. Metcalfe, R.
L. Stevens and R. A. Lewis, “Unique Features of Human
Basophilic Granulocytes Developed in in Vitro Culture,”
International Archives of Allergy and Applied Immun-
ology, Vol. 77, No. 1-2, 1985, pp. 137-143.
doi:10.1159/000233768
[12] L. J. Petersen, K. Brasso, M. Pryds and P. S. Skov, “His-
tamine Release in Intact Human Skin by Monocyte Che-
moattractant Factor-1, RANTES, Macrophage Inflamma-
tory Protein-1 Alpha, Stem Cell Factor, Anti-IgE, and Co-
deine as Determined by an ex Vivo Skin Microdialysis
Technique,” Journal of Allergy and Clinical Immunology,
Vol. 98, No. 4, 1996, pp. 790-796.
doi:10.1016/S0091-6749(96)70128-8
[13] L. K. Pershing, B. S. Silver, G. G. Krueger, V. P. Shah
and J. P. Skelly, “Feasibility of Measuring the Bioavai-
lability of Topical Betamethasone Dipropionate in Com-
mercial Formulations Using Drug Content in Skin and a
Blanching Bioassay,” Pharmaceutical Research, Vol. 9,
No. 1, 1992, pp. 45-51. doi:10.1023/A:1018975626210
[14] B. W. Barry and R. Woodford, “Activity and Bioavai-
lability of Topical Corticosteroids: In Vivo/In Vitro Cor-
relations for the Vasoconstrictor Test,” Journal of Clini-
cal Pharmacol ogy, Vol. 3, No. 1, 1978, pp. 43-65.
[15] K. H. Burdick, “Corticosteroid Bioavailability Assays:
Correlation with a Clinical Study,” Acta Dermato-Vene-
reologica: Supplement (Stockholm), Vol. 52, No. 67, 197 1,
pp. 19-23.
[16] B. W. Barry, “Bioavailability of Topical Steroids,” Der-
matologica, Vol. 152, Suppl. 1, 1976, pp. 47-65.
doi:10.1159/000257866
[17] G. L. Coleman, I. Kanfer and J. M. Haigh, “Comparative
Blanching Activities of Proprietary Diflucortolone Vale-
rate Topical Prepa rations,” Dermatologica, Vol. 156, No.
4, 1978, pp. 224-230. doi:10.1159/000250920
[18] E. Meyer, A. D. Magnus, J. M. Haigh and I. Kanfer,
“Comparison of the Blanching Activities of Dermovate,
Betnovate and Eumovate Creams and Ointments,” Inter-
national Journal of Pharmaceutics, Vol. 41, No. 1, 1988,
pp. 63-66. doi:10.1016/0378-5173(88)90136-6
[19] E. W. Smith, E. Meyer, J. M. Haigh and H. I. Maibach,
“The Human Skin Blanching Assay as an Indicator of To-
pical Corticosteroid Bioavailability and Potency: An Up-
date,” In: R. L. Bronaugh and H. I. Maibach, Eds., Per-
cutaneous Absorption: Mechanisms, Methodology and
Drug Delivery, 2nd Edition, Marcel Dekker, Inc., New
York, 1989, pp. 443-460.
[20] J. M. Haigh and L. Kanfer, “Assessment of Topical Cor-
ticosteroid Preparations: The Human Skin Blanching As-
say,” International Journal of Pharmaceutics, Vol. 19,
No. 3, 1984, pp. 245-262.
doi:10.1016/0378-5173(84)90055-3
Copyright © 2013 SciRes. JCDSA